New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:09 EDTINOInovio inititates DNA immunotherapy trial for several types of cancer
Subscribe for More Information
December 17, 2014
08:06 EDTINOInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use